title: Purification of Tannery Effluent by electrolytic corrosion of aluminium

authors: Mathieson, Grant Alexander

subjects: Tannery Effluent

abstract: Tannery Effluent is noxious because tanning process chemicals are preservatives, including chromium, and the pH is high. Electrolytic processing is feasible because the high salt content gives a high electrical conductivity. While research on the subject dates back to early in the 20th Century, commercialization has not occurred, perhaps due to excessive power consumption. Other researchers have produced promising results with rendering plant effluent (Tetrault 2003). During 2005 a specialised proprietary prototype with a novel anode design was trialed extensively at a Tannery site in New Zealand and produced good results during continuous inline operation despite wide variation in the inflow. Greater than 90% removal of chromium from solution with similar reductions in turbidity were achieved at lower operating cost, residual aluminum and total aluminum addition than by dosing with usual commercial aluminum based flocculants. Results from the field trials are shown and discussed.

text: Purification of Tannery Effluent by electrolytic corrosion of aluminium Tannery Effluent is noxious because tanning process chemicals are preservatives, including chromium, and the pH is high. Electrolytic processing is feasible because the high salt content gives a high electrical conductivity. While research on the subject dates back to early in the 20th Century, commercialization has not occurred, perhaps due to excessive power consumption. Other researchers have produced promising results with rendering plant effluent (Tetrault 2003). During 2005 a specialised proprietary prototype with a novel anode design was trialed extensively at a Tannery site in New Zealand and produced good results during continuous inline operation despite wide variation in the inflow. Greater than 90% removal of chromium from solution with similar reductions in turbidity were achieved at lower operating cost, residual aluminum and total aluminum addition than by dosing with usual commercial aluminum based flocculants. Results from the field trials are shown and discussed.

year: 2006

title: Sources of stress and students' perceptions of their wellbeing during work placement

authors: Zegwaard, Karsten E.

subjects: Finances

abstract: Wellbeing in society has been subject to increasing discussion, with particular attention to students engaged in higher education. Students in higher education experience stress related to studies and finances in addition to experiencing two major life changes – shifting from school learning to more self-directed learning and becoming more independent and self-reliant. Work placements add further challenges for students, therefore, there is a need to gain new knowledge on the relationship between placements, wellbeing stressors, and support mechanisms to better understand placement challenges and mitigate impacts on students. A total of 146 students who recently completed work placements participated in an anonymous survey and results indicated that students almost unanimously encountered financial stress even if in paid work placements and made lifestyle choices in response to stress that may harm their wellbeing. Students also reported having to actively manage stress but held positive views about life comparable to the general population.

text: Sources of stress and students' perceptions of their wellbeing during work placement Wellbeing in society has been subject to increasing discussion, with particular attention to students engaged in higher education. Students in higher education experience stress related to studies and finances in addition to experiencing two major life changes – shifting from school learning to more self-directed learning and becoming more independent and self-reliant. Work placements add further challenges for students, therefore, there is a need to gain new knowledge on the relationship between placements, wellbeing stressors, and support mechanisms to better understand placement challenges and mitigate impacts on students. A total of 146 students who recently completed work placements participated in an anonymous survey and results indicated that students almost unanimously encountered financial stress even if in paid work placements and made lifestyle choices in response to stress that may harm their wellbeing. Students also reported having to actively manage stress but held positive views about life comparable to the general population.

year: 2025

title: Real world initiation of newly funded empagliflozin and dulaglutide under special authority for patients with type 2 diabetes in New Zealand

authors: Chepulis, Lynne Merran

subjects: GLP1RA

abstract: Background: Type 2 diabetes (T2D) is sub-optimally managed for many in Aotearoa New Zealand, and disproportionately affects Māori and Pacific peoples. In February 2021, SGLT2i/GLP1RA agents were funded for use for the first time with prioritisation for Māori, Pacific and those with cardiovascular and/or renal disease or risk (CVRD). This study evaluates the impact of health system factors on initiation of SGLT2i/GLP1RA therapy. 

Methods: Primary care data was collected for patients with T2D aged 18–75 years from four primary care organisations (302 general practices) in the Auckland / Waikato region of New Zealand (Feb 2021 – July 2022). Initiation of SGLT2i/GLP1RA therapy was reviewed by patient (age, gender, ethnicity, CVRD status) and health system variables (funding, provider type, staffing, patient numbers, rurality, after-hours access). Logistic regression was used to estimate the odds ratio of a patient being dispensed SGLT2i/GLP1RA. 

Results: Of 57,743 patients with T2D, 22,331 were eligible for funded SGLT2i/GLP1RA access and 10,272 of those (46.0%) were prescribed. Initiation of therapy was highest in Māori (50.8%) and Pacific (48.8%) patients (vs. 36·2–40·7% of other ethnic groups; P < 0.001), but was comparable in those with and without CVRD (47·1% vs. 48·9%; P = 0.2). Prescribing was highest in practices with higher doctor/patient numbers, low-cost fees, Māori health providers and clinics without after-hours access.

Conclusion: Prioritised access for SGLT2i/GLP1RA appears to be associated with a reduced health equity gap for Māori and Pacific patients with T2D in NZ, but work is required to improve prescribing for patients with CVRD.

text: Real world initiation of newly funded empagliflozin and dulaglutide under special authority for patients with type 2 diabetes in New Zealand Background: Type 2 diabetes (T2D) is sub-optimally managed for many in Aotearoa New Zealand, and disproportionately affects Māori and Pacific peoples. In February 2021, SGLT2i/GLP1RA agents were funded for use for the first time with prioritisation for Māori, Pacific and those with cardiovascular and/or renal disease or risk (CVRD). This study evaluates the impact of health system factors on initiation of SGLT2i/GLP1RA therapy. 

Methods: Primary care data was collected for patients with T2D aged 18–75 years from four primary care organisations (302 general practices) in the Auckland / Waikato region of New Zealand (Feb 2021 – July 2022). Initiation of SGLT2i/GLP1RA therapy was reviewed by patient (age, gender, ethnicity, CVRD status) and health system variables (funding, provider type, staffing, patient numbers, rurality, after-hours access). Logistic regression was used to estimate the odds ratio of a patient being dispensed SGLT2i/GLP1RA. 

Results: Of 57,743 patients with T2D, 22,331 were eligible for funded SGLT2i/GLP1RA access and 10,272 of those (46.0%) were prescribed. Initiation of therapy was highest in Māori (50.8%) and Pacific (48.8%) patients (vs. 36·2–40·7% of other ethnic groups; P < 0.001), but was comparable in those with and without CVRD (47·1% vs. 48·9%; P = 0.2). Prescribing was highest in practices with higher doctor/patient numbers, low-cost fees, Māori health providers and clinics without after-hours access.

Conclusion: Prioritised access for SGLT2i/GLP1RA appears to be associated with a reduced health equity gap for Māori and Pacific patients with T2D in NZ, but work is required to improve prescribing for patients with CVRD.

year: 2025